News
18h
Barchart on MSNAs Q2 Deliveries Plunge 14%, Is Tesla Stock a Buy, Sell, or Hold?Tesla (TSLA) tumbled nearly 7% on Monday, July 7 as the electric vehicle giant grapples with declining deliveries and CEO ...
18h
Barchart on MSNMicrosoft Stock Has Outperformed in 2025. Can It Keep Going?There has been a divergence in the fortunes of the “Magnificent 7” stocks this year. Tesla (TSLA), Alphabet (GOOG), and Apple ...
17h
Cryptopolitan on MSNOPEC sees oil demand jumping 19% by 2050, and they’re betting on itOPEC is sticking to its guns while everyone else is screaming climate emergency. The cartel now says global oil demand will hit 123 million barrels a day by ...
Earnings are expected to be around $0.44 per share, according to consensus estimates, reflecting a 15% drop compared to the ...
Despite these issues, Tesla investors appear to be convinced that the company will experience a surge in sales trends at some ...
The annual meeting will be in November, nearly four months after what is required under Texas law. Tesla said on Thursday ...
Tesla faces declining sales, intense competition, and overhyped ventures while leadership concerns grow and FSD lags peers.
Tesla finally announced the date of its annual meeting. That’s after dozens of angry shareholders asked what was taking it so long.
The global green hydrogen market is experiencing robust growth, projected to reach between USD 100 billion to USD 120 billion ...
8h
Zacks.com on MSNRecursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth KnowingIn the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $5.72, marking a +2.24% move from the previous day.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results